Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.

[1]  J. Liao,et al.  Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway. , 2014, Cancer letters.

[2]  Thomas Hankemeier,et al.  A Protective Lipidomic Biosignature Associated with a Balanced Omega-6/Omega-3 Ratio in fat-1 Transgenic Mice , 2014, PloS one.

[3]  M. Arita,et al.  Eicosapentaenoic acid is converted via ω‐3 epoxygenation to the anti‐inflammatory metabolite 12‐hydroxy‐17,18‐epoxyeicosatetraenoic acid , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S. Hwang,et al.  Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis , 2013, Proceedings of the National Academy of Sciences.

[5]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[6]  Pei H. Cui,et al.  The ω‐3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down‐regulation , 2011, British journal of pharmacology.

[7]  R. Albadine,et al.  17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. , 2010, American journal of respiratory cell and molecular biology.

[8]  G. Wallukat,et al.  Arachidonic Acid-metabolizing Cytochrome P450 Enzymes Are Targets of ω-3 Fatty Acids* , 2010, The Journal of Biological Chemistry.

[9]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[10]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[11]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[12]  Jun Yang,et al.  Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. , 2009, Analytical chemistry.

[13]  S. Hwang,et al.  Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo , 2009, Molecular Cancer Therapeutics.

[14]  Jie Liao,et al.  CAAX-box protein, prenylation process and carcinogenesis. , 2009, American journal of translational research.

[15]  Y. Tesfaigzi,et al.  How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? , 2009, Cell cycle.

[16]  Paul D. Jones,et al.  Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation , 2009, British journal of pharmacology.

[17]  S. Hwang,et al.  Orally bioavailable potent soluble epoxide hydrolase inhibitors. , 2007, Journal of medicinal chemistry.

[18]  B. Hammock,et al.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[20]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[21]  B. Hammock,et al.  Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. , 2004, Journal of medicinal chemistry.

[22]  B. Riedl,et al.  Design and discovery of small molecules targeting raf-1 kinase. , 2002, Current pharmaceutical design.

[23]  D. Jump.  The Biochemistry of n-3 Polyunsaturated Fatty Acids* 210 , 2002, The Journal of Biological Chemistry.

[24]  William L. Smith,et al.  Structure of Eicosapentaenoic and Linoleic Acids in the Cyclooxygenase Site of Prostaglandin Endoperoxide H Synthase-1* , 2001, The Journal of Biological Chemistry.

[25]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[26]  William L. Smith,et al.  Fatty Acid Substrate Specificities of Human Prostaglandin-endoperoxide H Synthase-1 and −2 , 1995, The Journal of Biological Chemistry.

[27]  J K McLaughlin,et al.  Pancreatitis and the risk of pancreatic cancer. , 1993, The New England journal of medicine.

[28]  J. Liao,et al.  Inflammatory bowel disease: a model of chronic inflammation-induced cancer. , 2009, Methods in molecular biology.

[29]  Bruce D Hammock,et al.  Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). , 2007, Prostaglandins & other lipid mediators.

[30]  M. Löhr,et al.  Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. , 2005, Neoplasia.

[31]  B. Hammock,et al.  Epoxide hydrolases: their roles and interactions with lipid metabolism. , 2005, Progress in lipid research.

[32]  D. Rattner,et al.  Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. , 1997, Surgery.

[33]  A. Andrén-sandberg,et al.  Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. , 1993, The New England journal of medicine.